查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1405886

POC（护理点）分子诊断市场规模、份额、趋势分析报告：按应用、按技术、按测试地点、按最终用途、按地区、细分市场预测，2024-2030 年

Point-of-Care Molecular Diagnostics Market Size, Share & Trends Analysis Report By Application (Infectious Diseases, Oncology, Prenatal Testing), By Technology, By Test Location, By End-use, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

POC（即时护理）分子诊断市场成长与趋势：

Grand View Research, Inc.最新报告显示，2030年全球POC（Point-of-Care）分子诊断市场规模将达到101.2亿美元，2024年至2030年复合年增长率为2.5%。预计。

预计 COVID-19、HIV、HBC 和 HCV 等感染疾病的上升以及老年人口的增长将推动对 POC 分子诊断测试的需求。此外，这些 POC 测试提供的快速、准确的结果是其在全部区域日益被接受的关键因素。此外，新兴国家居家医疗和护理设施的重要性日益增加，预计也将推动预测期内 POC 分子诊断市场的成长。

全球老年人口不断增加，预计将推动对 POC 分子诊断的需求。根据世界卫生组织发布的估计，全球65岁及以上人口预计将从2000年的7%增加到2050年的16%。高龄化会增加心血管疾病和癌症等疾病的风险。因此，全球老年人口的增加预计将增加对透过需要 POC MDx 的设施（例如家庭医疗保健和辅助生活医疗保健设施）进行持续监测的需求。日本和中国是受影响最严重的亚洲国家之一，日本的老年人口预计将大幅增加。目前，日本超过20%的人口年龄在65岁以上。

各国癌症盛行率不断上升，导致对院内护理点 (POC) 分子诊断测试的持续需求。根据国家慢性病预防与健康促进中心预测，每年癌症患者人数预计将从2015年的153万人增加到2050年的228万人。此外，用于癌症检测的 CRISPR 和 NGS 技术的出现极大地提高了诊断率。过去十年 NGS 的承受能力不断提高也使肿瘤 POC 分子诊断市场受益。这些因素可能会推动全球市场。

参与POC分子诊断市场的主要公司包括丹纳赫、生物梅里埃、Bio-Rad Laboratories、雅培、F. Hoffman La Roche和BD。很可能会推出许多试验计画，并且新产品将出现在市场上。例如，2022 年 3 月，Intermountain Healthcare 宣布将向 50 名员工推出 Galleri 多种癌症早期检测测试作为试点。

POC（即时护理）分子诊断市场报告亮点

  • 从技术角度来看，由于诊断 COVID-19 和其他感染疾病的RT-PCR 测试的需求不断增加，基于 PCR 的细分市场在 POC（即时护理）分子诊断市场中占据了主要份额。
  • 由于医院、诊所和门诊中心选择快速 POC 检测的需求不断增加，预计 POC 检测地点部分在预测期内将显着增长。
  • 由于对新技术的需求不断增加、关键参与者众多、癌症和感染疾病病率上升以及先进的医疗基础设施，2023 年的全球市场将由北美主导。
  • 由于医疗基础设施的改善和癌症检测意识的提高，预计亚太地区未来几年将出现强劲增长。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章市场变数、趋势和范围

  • 市场区隔和范围
  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
  • 市场驱动因素
  • 市场抑制因素分析
  • 营商环境分析
    • SWOT 分析；按因素（政治/法律、经济/技术）
    • 波特五力分析
    • COVID-19感染疾病的影响分析

第四章技术商业分析

  • POC（即时护理）分子诊断市场：技术变化分析
  • 基于PCR的
  • 基于基因序列
  • 杂合反应基地
  • 微阵列基底

第 5 章应用程式的商业分析

  • POC（即时护理）分子诊断市场：应用变化分析
  • 感染疾病
    • HIV POC
    • 困难梭状芽孢桿菌POC
    • HBV POC
    • 肺炎或链球菌相关感染疾病
    • 呼吸道融合细胞病毒(RSV) POC
    • HPV POC
    • 流感/流感 POC
    • HCV POC
    • MRSA POC
    • 结核病和抗药性结核病的 POC
    • HSV POC
    • 其他感染疾病
  • 肿瘤学
  • 血液学
  • 产前检测
  • 内分泌学
  • 其他的

第六章 检验中心业务分析

  • POC（Point of Care）分子诊断市场：检测中心波动分析
  • OTC
  • POC

第 7 章最终用途业务分析

  • POC（即时护理）分子诊断市场：最终用途变异分析
  • 分散式实验室
  • 医院
  • 居家照护
  • 生活支援医疗设施
  • 其他的

第八章区域业务分析

  • 2023 年和 2030 年 POC（即时护理）分子诊断市场占有率（按地区）
  • 北美洲
    • 北美POC（Point of Care）分子诊断市场，2018-2030
    • 美国
    • 加拿大
  • 欧洲
    • 欧洲POC（即时照护）分子诊断市场，2018-2030
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 亚太地区POC（床边）分子诊断市场，2018-2030
    • 日本
    • 中国
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 拉丁美洲护理点分子诊断市场，2018-2030
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东/非洲
    • MEAPOC（护理点）分子诊断市场，2018-2030
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第9章竞争形势

  • 参与企业概况
  • 财务绩效
  • 参与企业
    • 市场领导者
    • POC（即时照护）分子诊断市场占有率分析，2023 年
    • 公司简介
    • 策略规划
Product Code: 978-1-68038-886-2

Point-of-Care Molecular Diagnostics Market Growth & Trends:

The global point-of-care molecular diagnostics market size is expected to reach USD 10.12 billion by 2030, registering a CAGR of 2.5% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rising prevalence of infectious diseases such as COVID-19, HIV, HBC, HCV, along with growing geriatric population is predicted to fuel the need for POC molecular diagnostics tests. Furthermore, rapid and accurate results offered by these POC tests act as a major factor for such growing acceptance across geographies. Moreover, rising emphasis for home care and assisted care facilities across emerging economies is also predicted boost POC molecular diagnostics market growth during the forecast years.

Global geriatric population is increasing, which is expected to boost the demand for POC molecular diagnostics. Estimates published by the WHO suggest that the global population of age group 65 years and above is expected to increase from 7% in 2000 to 16% in 2050. Aging elevates the risk of diseases such as cardiovascular and cancer. Therefore, increase in global geriatric population is expected to raise the demand for continuous monitoring via facilities requiring POC MDx, such as home healthcare and assisted living healthcare facilities. Japan and China are two of the most affected Asian countries, and a significant increase in Japan's geriatric population is anticipated. Currently, more than 20% of the country's population is over the age of 65 years.

Increasing prevalence of cancer across countries has resulted in a continuous demand for point-of-care molecular diagnostic tests within hospitals. According to the National Center for Chronic Disease Prevention and Health Promotion, the annual cancer cases are likely to grow from 1.53 million in 2015 to 2.28 million by 2050. CDC has predicted incidence is likely to increase by 50% owing to increasing population within the U.S. Furthermore, emergence of CRISPR and NGS techniques for cancer detection has improved the diagnosis rates tremendously. With increasing affordability of NGS in past decade has also benefited the POC molecular diagnostics market for oncology. Such factors are likely to drive the global market.

Major companies active in the POC molecular diagnostics market include Danaher, BioMerieux, Bio-Rad Laboratories, Inc., Abbott, F. Hoffmann-La Roche AG, BD, and many more. Large number of pilot programs being initiated are likely to bring new products in the market. For instance, in march 2022, Intermountain Healthcare announced that they will be rolling out a Galleri Multi-Cancer Early Detection Test for 50 of their employees as a pilot plan, with this the company is expecting to launch new product in order to improve their market position.

Point-of-Care Molecular Diagnostics Market Report Highlights:

  • By technology, the PCR-based segment held a larger share of the point-of-care molecular diagnostics market owing to increasing demand for RT-PCR tests for diagnosis of COVID-19 and other infectious diseases
  • The POC test location segment is expected to grow lucratively over the forecast period due to rising demand from hospitals, clinics and ambulatory centers opting for rapid POC tests
  • North America dominated the global market in 2023, owing to increasing demand for new technologies, a large pool of key players, rising prevalence of cancer, infectious diseases, and advanced healthcare infrastructure
  • The Asia Pacific is expected to grow considerably in the future owing to due to the growing healthcare infrastructure and rising awareness of cancer testing within the region

Table of Contents

Chapter 1. Methodology And Scope

  • 1.1. Market Segmentation
    • 1.1.1. Market Definitions
  • 1.2. Objectives
    • 1.2.1. Objective - 1
    • 1.2.2. Objective - 2
    • 1.2.3. Objective - 3
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. Gvr's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information Or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Abbreviations
  • 1.10. List of Primary Sources

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers
  • 3.5. Market Restraint Analysis
  • 3.6. Business Environment Analysis
    • 3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
    • 3.6.2. Porter's Five Forces Analysis
    • 3.6.3. COVID-19 Impact Analysis

Chapter 4. Technology Business Analysis

  • 4.1. Point-of-Care Molecular Diagnostics market: Technology Movement Analysis
  • 4.2. PCR-based
    • 4.2.1. PCR-based Market, 2018 - 2030 (USD Million)
  • 4.3. Genetic Sequencing-based
    • 4.3.1. Genetic Sequencing-based Market, 2018 - 2030 (USD Million)
  • 4.4. Hybridization-based
    • 4.4.1. Hybridization-based Market, 2018 - 2030 (USD Million)
  • 4.5. Microarray-based
    • 4.5.1. Microarray-based Market, 2018 - 2030 (USD Million)

Chapter 5. Application Business Analysis

  • 5.1. Point-of-Care Molecular Diagnostics Market: Application Movement Analysis
  • 5.2. Infectious Diseases
    • 5.2.1. Infectious Diseases Market, 2018 - 2030 (USD Million)
    • 5.2.2. HIV POC
      • 5.2.2.1. HIV POC Market, 2018 - 2030 (USD Million)
    • 5.2.3. Clostridium difficile POC
      • 5.2.3.1. Clostridium difficile POC Market, 2018 - 2030 (USD Million)
    • 5.2.4. HBV POC
      • 5.2.4.1. HBV POC Market, 2018 - 2030 (USD Million)
    • 5.2.5. Pneumonia or Streptococcus associated infections
      • 5.2.5.1. Pneumonia or Streptococcus associated infections Market, 2018 - 2030 (USD Million)
    • 5.2.6. Respiratory Syncytial Virus (RSV) POC
      • 5.2.6.1. Respiratory Syncytial Virus (RSV) POC Market, 2018 - 2030 (USD Million)
    • 5.2.7. HPV POC
      • 5.2.7.1. HPV POC Market, 2018 - 2030 (USD Million)
    • 5.2.8. Influenza/Flu POC
      • 5.2.8.1. Influenza/Flu POC Market, 2018 - 2030 (USD Million)
    • 5.2.9. HCV POC
      • 5.2.9.1. HCV POC Market, 2018 - 2030 (USD Million)
    • 5.2.10. MRSA POC
      • 5.2.10.1. MRSA POC Market, 2018 - 2030 (USD Million)
    • 5.2.11. TB and drug-resistant TB POC
      • 5.2.11.1. TB and drug-resistant TB POC Market, 2018 - 2030 (USD Million)
    • 5.2.12. HSV POC
      • 5.2.12.1. HSV POC Market, 2018 - 2030 (USD Million)
    • 5.2.13. Other Infectious Diseases
      • 5.2.13.1. Other Infectious Diseases Market, 2018 - 2030 (USD Million)
  • 5.3. Oncology
    • 5.3.1. Oncology Market, 2018 - 2030 (USD Million)
  • 5.4. Hematology
    • 5.4.1. Hematology Market, 2018 - 2030 (USD Million)
  • 5.5. Prenatal Testing
    • 5.5.1. Prenatal Testing Market, 2018 - 2030 (USD Million)
  • 5.6. Endocrinology
    • 5.6.1. Endocrinology Market, 2018 - 2030 (USD Million)
  • 5.7. Others
    • 5.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Test Location Business Analysis

  • 6.1. Point-of-Care Molecular Diagnostics Market: Test Location Movement Analysis
  • 6.2. OTC
    • 6.2.1. OTC Market, 2018 - 2030 (USD Million)
  • 6.3. POC
    • 6.3.1. POC Market, 2018 - 2030 (USD Million)

Chapter 7. End-use Business Analysis

  • 7.1. Point-of-Care Molecular Diagnostics Market: End-Use Movement Analysis
  • 7.2. Decentralized Labs
    • 7.2.1. Decentralized Labs Market, 2018 - 2030 (USD Million)
  • 7.3. Hospitals
    • 7.3.1. Hospitals Market, 2018 - 2030 (USD Million)
  • 7.4. Home-care
    • 7.4.1. Home-care Market, 2018 - 2030 (USD Million)
  • 7.5. Assisted Living Healthcare Facilities
    • 7.5.1. Assisted Living Healthcare Facilities Market, 2018 - 2030 (USD Million)
  • 7.6. Others
    • 7.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 8. Regional Business Analysis

  • 8.1. Point-of-Care Molecular Diagnostics Market Share By Region, 2023 & 2030
  • 8.2. North America
    • 8.2.1. North America Point-of-Care Molecular Diagnostics market, 2018 - 2030 (USD Million)
    • 8.2.2. U.S.
      • 8.2.2.1. Key Country Dynamics
      • 8.2.2.2. Target Disease Prevalence
      • 8.2.2.3. Competitive Scenario
      • 8.2.2.4. Regulatory Framework
      • 8.2.2.5. Reimbursement Scenario
      • 8.2.2.6. U.S. Point-of-Care Molecular Diagnostics market, 2018 - 2030 (USD MILLION)
    • 8.2.3. Canada
      • 8.2.3.1. Key Country Dynamics
      • 8.2.3.2. Target Disease Prevalence
      • 8.2.3.3. Competitive Scenario
      • 8.2.3.4. Regulatory Framework
      • 8.2.3.5. Reimbursement Scenario
      • 8.2.3.6. Canada Point-of-Care Molecular Diagnostics market, 2018 - 2030 (USD Million)
  • 8.3. Europe
    • 8.3.1. Europe Point-of-Care Molecular Diagnostics market, 2018 - 2030 (USD Million)
    • 8.3.2. Germany
      • 8.3.2.1. Key Country Dynamics
      • 8.3.2.2. Target Disease Prevalence
      • 8.3.2.3. Competitive Scenario
      • 8.3.2.4. Regulatory Framework
      • 8.3.2.5. Reimbursement Scenario
      • 8.3.2.6. Germany Point-of-Care Molecular Diagnostics market, 2018 - 2030 (USD Million)
    • 8.3.3. UK
      • 8.3.3.1. Key Country Dynamics
      • 8.3.3.2. Target Disease Prevalence
      • 8.3.3.3. Competitive Scenario
      • 8.3.3.4. Regulatory Framework
      • 8.3.3.5. Reimbursement Scenario
      • 8.3.3.6. UK Point-of-Care Molecular Diagnostics market, 2018 - 2030 (USD Million)
    • 8.3.4. France
      • 8.3.4.1. Key Country Dynamics
      • 8.3.4.2. Target Disease Prevalence
      • 8.3.4.3. Competitive Scenario
      • 8.3.4.4. Regulatory Framework
      • 8.3.4.5. Reimbursement Scenario
      • 8.3.4.6. France Point-of-Care Molecular Diagnostics market, 2018 - 2030 (USD Million)
    • 8.3.5. Italy
      • 8.3.5.1. Key Country Dynamics
      • 8.3.5.2. Target Disease Prevalence
      • 8.3.5.3. Competitive Scenario
      • 8.3.5.4. Regulatory Framework
      • 8.3.5.5. Reimbursement Scenario
      • 8.3.5.6. Italy Point-of-Care Molecular Diagnostics market, 2018 - 2030 (USD Million)
    • 8.3.6. Spain
      • 8.3.6.1. Key Country Dynamics
      • 8.3.6.2. Target Disease Prevalence
      • 8.3.6.3. Competitive Scenario
      • 8.3.6.4. Regulatory Framework
      • 8.3.6.5. Reimbursement Scenario
      • 8.3.6.6. Spain Point-of-Care Molecular Diagnostics market, 2018 - 2030 (USD Million)
    • 8.3.7. Denmark
      • 8.3.7.1. Key Country Dynamics
      • 8.3.7.2. Target Disease Prevalence
      • 8.3.7.3. Competitive Scenario
      • 8.3.7.4. Regulatory Framework
      • 8.3.7.5. Reimbursement Scenario
      • 8.3.7.6. Denmark Point-of-Care Molecular Diagnostics market, 2018 - 2030 (USD Million)
    • 8.3.8. Sweden
      • 8.3.8.1. Key Country Dynamics
      • 8.3.8.2. Target Disease Prevalence
      • 8.3.8.3. Competitive Scenario
      • 8.3.8.4. Regulatory Framework
      • 8.3.8.5. Reimbursement Scenario
      • 8.3.8.6. Sweden Point-of-Care Molecular Diagnostics market, 2018 - 2030 (USD Million)
    • 8.3.9. Norway
      • 8.3.9.1. Key Country Dynamics
      • 8.3.9.2. Target Disease Prevalence
      • 8.3.9.3. Competitive Scenario
      • 8.3.9.4. Regulatory Framework
      • 8.3.9.5. Reimbursement Scenario
      • 8.3.9.6. Norway Point-of-Care Molecular Diagnostics market, 2018 - 2030 (USD Million)
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific Point-of-Care Molecular Diagnostics market, 2018 - 2030 (USD Million)
    • 8.4.2. Japan
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Target Disease Prevalence
      • 8.4.2.3. Competitive Scenario
      • 8.4.2.4. Regulatory Framework
      • 8.4.2.5. Reimbursement Scenario
      • 8.4.2.6. Japan Point-of-Care Molecular Diagnostics market, 2018 - 2030 (USD Million)
    • 8.4.3. China
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Target Disease Prevalence
      • 8.4.3.3. Competitive Scenario
      • 8.4.3.4. Regulatory Framework
      • 8.4.3.5. Reimbursement Scenario
      • 8.4.3.6. China Point-of-Care Molecular Diagnostics market, 2018 - 2030 (USD Million)
    • 8.4.4. India
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Target Disease Prevalence
      • 8.4.4.3. Competitive Scenario
      • 8.4.4.4. Regulatory Framework
      • 8.4.4.5. Reimbursement Scenario
      • 8.4.4.6. India Point-of-Care Molecular Diagnostics market, 2018 - 2030 (USD Million)
    • 8.4.5. South Korea
      • 8.4.5.1. Key Country Dynamics
      • 8.4.5.2. Target Disease Prevalence
      • 8.4.5.3. Competitive Scenario
      • 8.4.5.4. Regulatory Framework
      • 8.4.5.5. Reimbursement Scenario
      • 8.4.5.6. South Korea Point-of-Care Molecular Diagnostics market, 2018 - 2030 (USD Million)
    • 8.4.6. Australia
      • 8.4.6.1. Key Country Dynamics
      • 8.4.6.2. Target Disease Prevalence
      • 8.4.6.3. Competitive Scenario
      • 8.4.6.4. Regulatory Framework
      • 8.4.6.5. Reimbursement Scenario
      • 8.4.6.6. Australia Point-of-Care Molecular Diagnostics market, 2018 - 2030 (USD Million)
    • 8.4.7. Thailand
      • 8.4.7.1. Key Country Dynamics
      • 8.4.7.2. Target Disease Prevalence
      • 8.4.7.3. Competitive Scenario
      • 8.4.7.4. Regulatory Framework
      • 8.4.7.5. Reimbursement Scenario
      • 8.4.7.6. Thailand Point-of-Care Molecular Diagnostics market, 2018 - 2030 (USD Million)
  • 8.5. Latin America
    • 8.5.1. Latin America Point-of-Care Molecular Diagnostics market, 2018 - 2030 (USD Million)
    • 8.5.2. Brazil
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Target Disease Prevalence
      • 8.5.2.3. Competitive Scenario
      • 8.5.2.4. Regulatory Framework
      • 8.5.2.5. Reimbursement Scenario
      • 8.5.2.6. Brazil Point-of-Care Molecular Diagnostics market, 2018 - 2030 (USD Million)
    • 8.5.3. Mexico
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Target Disease Prevalence
      • 8.5.3.3. Competitive Scenario
      • 8.5.3.4. Regulatory Framework
      • 8.5.3.5. Reimbursement Scenario
      • 8.5.3.6. Mexico Point-of-Care Molecular Diagnostics market, 2018 - 2030 (USD Million)
    • 8.5.4. Argentina
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Target Disease Prevalence
      • 8.5.4.3. Competitive Scenario
      • 8.5.4.4. Regulatory Framework
      • 8.5.4.5. Reimbursement Scenario
      • 8.5.4.6. Argentina Point-of-Care Molecular Diagnostics market, 2018 - 2030 (USD Million)
  • 8.6. MEA
    • 8.6.1. MEA Point-of-Care Molecular Diagnostics market, 2018 - 2030 (USD Million)
    • 8.6.2. South Africa
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Target Disease Prevalence
      • 8.6.2.3. Competitive Scenario
      • 8.6.2.4. Regulatory Framework
      • 8.6.2.5. Reimbursement Scenario
      • 8.6.2.6. South Africa Point-of-Care Molecular Diagnostics market, 2018 - 2030 (USD Million)
    • 8.6.3. Saudi Arabia
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Target Disease Prevalence
      • 8.6.3.3. Competitive Scenario
      • 8.6.3.4. Regulatory Framework
      • 8.6.3.5. Reimbursement Scenario
      • 8.6.3.6. Saudi Arabia Point-of-Care Molecular Diagnostics market, 2018 - 2030 (USD Million)
    • 8.6.4. UAE
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Target Disease Prevalence
      • 8.6.4.3. Competitive Scenario
      • 8.6.4.4. Regulatory Framework
      • 8.6.4.5. Reimbursement Scenario
      • 8.6.4.6. UAE Point-of-Care Molecular Diagnostics market, 2018 - 2030 (USD Million)
    • 8.6.5. Kuwait
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Target Disease Prevalence
      • 8.6.5.3. Competitive Scenario
      • 8.6.5.4. Regulatory Framework
      • 8.6.5.5. Reimbursement Scenario
      • 8.6.5.6. Kuwait Point-of-Care Molecular Diagnostics market, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Participant's overview
  • 9.2. Financial performance
  • 9.3. Participant categorization
    • 9.3.1. Market Leaders
    • 9.3.2. Point-of-Care Molecular Diagnostics market Share Analysis, 2023
    • 9.3.3. Company Profiles
      • 9.3.3.1. Abbott
      • 9.3.3.1.1. Company Overview
      • 9.3.3.1.2. Financial Performance
      • 9.3.3.1.3. Product Benchmarking
      • 9.3.3.1.4. Strategic Initiatives
      • 9.3.3.2. Bayer AG
      • 9.3.3.2.1. Company Overview
      • 9.3.3.2.2. Financial Performance
      • 9.3.3.2.3. Product Benchmarking
      • 9.3.3.2.4. Strategic Initiatives
      • 9.3.3.3. F. Hoffmann-La Roche AG
      • 9.3.3.3.1. Company Overview
      • 9.3.3.3.2. Financial Performance
      • 9.3.3.3.3. Product Benchmarking
      • 9.3.3.3.4. Strategic Initiatives
      • 9.3.3.4. Nova Biomedical
      • 9.3.3.4.1. Company Overview
      • 9.3.3.4.2. Financial Performance
      • 9.3.3.4.3. Product Benchmarking
      • 9.3.3.4.4. Strategic Initiatives
      • 9.3.3.5. QIAGEN
      • 9.3.3.5.1. Company Overview
      • 9.3.3.5.2. Financial Performance
      • 9.3.3.5.3. Product Benchmarking
      • 9.3.3.5.4. Strategic Initiatives
      • 9.3.3.6. Nipro Diagnostics
      • 9.3.3.6.1. Company Overview
      • 9.3.3.6.2. Financial Performance
      • 9.3.3.6.3. Product Benchmarking
      • 9.3.3.6.4. Strategic Initiatives
      • 9.3.3.7. Danaher
      • 9.3.3.7.1. Company Overview
      • 9.3.3.7.2. Financial Performance
      • 9.3.3.7.3. Product Benchmarking
      • 9.3.3.7.4. Strategic Initiatives
      • 9.3.3.8. Bio-Rad Laboratories, Inc.
      • 9.3.3.8.1. Company Overview
      • 9.3.3.8.2. Financial Performance
      • 9.3.3.8.3. Product Benchmarking
      • 9.3.3.8.4. Strategic Initiatives
      • 9.3.3.9. bioMerieux
      • 9.3.3.9.1. Company Overview
      • 9.3.3.9.2. Financial Performance
      • 9.3.3.9.3. Product Benchmarking
      • 9.3.3.9.4. Strategic Initiatives
      • 9.3.3.10. Agilent Technologies, Inc.
      • 9.3.3.10.1. Company Overview
      • 9.3.3.10.2. Financial Performance
      • 9.3.3.10.3. Product Benchmarking
      • 9.3.3.10.4. Strategic Initiatives
      • 9.3.3.11. Abaxis
      • 9.3.3.11.1. Company Overview
      • 9.3.3.11.2. Financial Performance
      • 9.3.3.11.3. Product Benchmarking
      • 9.3.3.11.4. Strategic Initiatives
      • 9.3.3.12. OraSure Technologies
      • 9.3.3.12.1. Company Overview
      • 9.3.3.12.2. Financial Performance
      • 9.3.3.12.3. Product Benchmarking
      • 9.3.3.12.4. Strategic Initiatives
    • 9.3.4. Strategy Mapping
      • 9.3.4.1. Expansion
      • 9.3.4.2. Acquisition
      • 9.3.4.3. Collaborations
      • 9.3.4.4. Disease Type/Drug Class Launch
      • 9.3.4.5. Partnerships
      • 9.3.4.6. Others

List of Tables

  • TABLE 1 Point-of-care Molecular Diagnostics market - Industry Snapshot & Key Buying Criteria, 2018 - 2030
  • TABLE 2 Global Point-of-care Molecular Diagnostics market, by application, 2018 - 2030 (USD Million)
  • TABLE 3 Global Point-of-care Molecular Diagnostics market, by technology, 2018 - 2030 (USD Million)
  • TABLE 4 Global Point-of-care Molecular Diagnostics market, by test location, 2018 - 2030 (USD Million)
  • TABLE 5 Global Point-of-care Molecular Diagnostics market, by End-use, 2018 - 2030 (USD Million)
  • TABLE 6 Global Point-of-care Molecular Diagnostics market, by region, 2018 - 2030 (USD Million)
  • TABLE 7 Point-of-care Molecular Diagnostics- Key market driver analysis
  • TABLE 8 Point-of-care Molecular Diagnostics- Key market restraint analysis
  • TABLE 9 North America Point-of-care Molecular Diagnostics market, by country, 2018 - 2030 (USD Million)
  • TABLE 10 North America Point-of-care Molecular Diagnostics market, by application, 2018 - 2030 (USD Million)
  • TABLE 11 North America Point-of-care Molecular Diagnostics market, by technology, 2018 - 2030 (USD Million)
  • TABLE 12 North America Point-of-care Molecular Diagnostics market, by test location, 2018 - 2030 (USD Million)
  • TABLE 13 North America Point-of-care Molecular Diagnostics market, by End-use, 2018 - 2030 (USD Million)
  • TABLE 14 US Point-of-care Molecular Diagnostics market, by application, 2018 - 2030 (USD Million)
  • TABLE 15 US Point-of-care Molecular Diagnostics market, by technology, 2018 - 2030 (USD Million)
  • TABLE 16 US Point-of-care Molecular Diagnostics market, by test location, 2018 - 2030 (USD Million)
  • TABLE 17 US Point-of-care Molecular Diagnostics market, by End-use, 2018 - 2030 (USD Million)
  • TABLE 18 Canada Point-of-care Molecular Diagnostics market, by application, 2018 - 2030 (USD Million)
  • TABLE 19 Canada Point-of-care Molecular Diagnostics market, by technology, 2018 - 2030 (USD Million)
  • TABLE 20 Canada Point-of-care Molecular Diagnostics market, by test location, 2018 - 2030 (USD Million)
  • TABLE 21 Canada Point-of-care Molecular Diagnostics market, by End-use, 2018 - 2030 (USD Million)
  • TABLE 22 Europe Point-of-care Molecular Diagnostics market, by country, 2018 - 2030 (USD Million)
  • TABLE 23 Europe Point-of-care Molecular Diagnostics market, by application, 2018 - 2030 (USD Million)
  • TABLE 24 Europe Point-of-care Molecular Diagnostics market, by technology, 2018 - 2030 (USD Million)
  • TABLE 25 Europe Point-of-care Molecular Diagnostics market, by test location, 2018 - 2030 (USD Million)
  • TABLE 26 Europe Point-of-care Molecular Diagnostics market, by End-use, 2018 - 2030 (USD Million)
  • TABLE 27 Germany Point-of-care Molecular Diagnostics market, by application, 2018 - 2030 (USD Million)
  • TABLE 28 Germany Point-of-care Molecular Diagnostics market, by technology, 2018 - 2030 (USD Million)
  • TABLE 29 Germany Point-of-care Molecular Diagnostics market, by test location, 2018 - 2030 (USD Million)
  • TABLE 30 Germany Point-of-care Molecular Diagnostics market, by End-use, 2018 - 2030 (USD Million)
  • TABLE 31 UK Point-of-care Molecular Diagnostics market, by application, 2018 - 2030 (USD Million)
  • TABLE 32 UK Point-of-care Molecular Diagnostics market, by technology, 2018 - 2030 (USD Million)
  • TABLE 33 UK Point-of-care Molecular Diagnostics market, by test location, 2018 - 2030 (USD Million)
  • TABLE 34 UK Point-of-care Molecular Diagnostics market, by End-use, 2018 - 2030 (USD Million)
  • TABLE 35 France Point-of-care Molecular Diagnostics market, by application, 2018 - 2030 (USD Million)
  • TABLE 36 France Point-of-care Molecular Diagnostics market, by technology, 2018 - 2030 (USD Million)
  • TABLE 37 France Point-of-care Molecular Diagnostics market, by test location, 2018 - 2030 (USD Million)
  • TABLE 38 France Point-of-care Molecular Diagnostics market, by End-use, 2018 - 2030 (USD Million)
  • TABLE 39 Italy Point-of-care Molecular Diagnostics market, by application, 2018 - 2030 (USD Million)
  • TABLE 40 Italy Point-of-care Molecular Diagnostics market, by technology, 2018 - 2030 (USD Million)
  • TABLE 41 Italy Point-of-care Molecular Diagnostics market, by test location, 2018 - 2030 (USD Million)
  • TABLE 42 Italy Point-of-care Molecular Diagnostics market, by End-use, 2018 - 2030 (USD Million)
  • TABLE 43 Spain Point-of-care Molecular Diagnostics market, by application, 2018 - 2030 (USD Million)
  • TABLE 44 Spain Point-of-care Molecular Diagnostics market, by technology, 2018 - 2030 (USD Million)
  • TABLE 45 Spain Point-of-care Molecular Diagnostics market, by test location, 2018 - 2030 (USD Million)
  • TABLE 46 Spain Point-of-care Molecular Diagnostics market, by End-use, 2018 - 2030 (USD Million)
  • TABLE 47 Denmark Point-of-care Molecular Diagnostics market, by application, 2018 - 2030 (USD Million)
  • TABLE 48 Denmark Point-of-care Molecular Diagnostics market, by technology, 2018 - 2030 (USD Million)
  • TABLE 49 Denmark Point-of-care Molecular Diagnostics market, by test location, 2018 - 2030 (USD Million)
  • TABLE 50 Denmark Point-of-care Molecular Diagnostics market, by End-use, 2018 - 2030 (USD Million)
  • TABLE 51 Sweden Point-of-care Molecular Diagnostics market, by application, 2018 - 2030 (USD Million)
  • TABLE 52 Sweden Point-of-care Molecular Diagnostics market, by technology, 2018 - 2030 (USD Million)
  • TABLE 53 Sweden Point-of-care Molecular Diagnostics market, by test location, 2018 - 2030 (USD Million)
  • TABLE 54 Sweden Point-of-care Molecular Diagnostics market, by End-use, 2018 - 2030 (USD Million)
  • TABLE 55 Norway Point-of-care Molecular Diagnostics market, by application, 2018 - 2030 (USD Million)
  • TABLE 56 Norway Point-of-care Molecular Diagnostics market, by technology, 2018 - 2030 (USD Million)
  • TABLE 57 Norway Point-of-care Molecular Diagnostics market, by test location, 2018 - 2030 (USD Million)
  • TABLE 58 Norway Point-of-care Molecular Diagnostics market, by End-use, 2018 - 2030 (USD Million)
  • TABLE 59 Asia Pacific Point-of-care Molecular Diagnostics market, by country, 2018 - 2030 (USD Million)
  • TABLE 60 Asia Pacific Point-of-care Molecular Diagnostics market, by application, 2018 - 2030 (USD Million)
  • TABLE 61 Asia Pacific Point-of-care Molecular Diagnostics market, by technology, 2018 - 2030 (USD Million)
  • TABLE 62 Asia Pacific Point-of-care Molecular Diagnostics market, by test location, 2018 - 2030 (USD Million)
  • TABLE 63 Asia Pacific Point-of-care Molecular Diagnostics market, by End-use, 2018 - 2030 (USD Million)
  • TABLE 64 Japan Point-of-care Molecular Diagnostics market, by application, 2018 - 2030 (USD Million)
  • TABLE 65 Japan Point-of-care Molecular Diagnostics market, by technology, 2018 - 2030 (USD Million)
  • TABLE 66 Japan Point-of-care Molecular Diagnostics market, by test location, 2018 - 2030 (USD Million)
  • TABLE 67 Japan Point-of-care Molecular Diagnostics market, by End-use, 2018 - 2030 (USD Million)
  • TABLE 68 China Point-of-care Molecular Diagnostics market, by application, 2018 - 2030 (USD Million)
  • TABLE 69 China Point-of-care Molecular Diagnostics market, by technology, 2018 - 2030 (USD Million)
  • TABLE 70 China Point-of-care Molecular Diagnostics market, by test location, 2018 - 2030 (USD Million)
  • TABLE 71 China Point-of-care Molecular Diagnostics market, by End-use, 2018 - 2030 (USD Million)
  • TABLE 72 India Point-of-care Molecular Diagnostics market, by application, 2018 - 2030 (USD Million)
  • TABLE 73 India Point-of-care Molecular Diagnostics market, by technology, 2018 - 2030 (USD Million)
  • TABLE 74 India Point-of-care Molecular Diagnostics market, by test location, 2018 - 2030 (USD Million)
  • TABLE 75 India Point-of-care Molecular Diagnostics market, by End-use, 2018 - 2030 (USD Million)
  • TABLE 76 Australia Point-of-care Molecular Diagnostics market, by application, 2018 - 2030 (USD Million)
  • TABLE 77 Australia Point-of-care Molecular Diagnostics market, by technology, 2018 - 2030 (USD Million)
  • TABLE 78 Australia Point-of-care Molecular Diagnostics market, by test location, 2018 - 2030 (USD Million)
  • TABLE 79 Australia Point-of-care Molecular Diagnostics market, by End-use, 2018 - 2030 (USD Million)
  • TABLE 80 South Korea Point-of-care Molecular Diagnostics market, by application, 2018 - 2030 (USD Million)
  • TABLE 81 South Korea Point-of-care Molecular Diagnostics market, by technology, 2018 - 2030 (USD Million)
  • TABLE 82 South Korea Point-of-care Molecular Diagnostics market, by test location, 2018 - 2030 (USD Million)
  • TABLE 83 South Korea Point-of-care Molecular Diagnostics market, by End-use, 2018 - 2030 (USD Million)
  • TABLE 84 Thailand Point-of-care Molecular Diagnostics market, by application, 2018 - 2030 (USD Million)
  • TABLE 85 Thailand Point-of-care Molecular Diagnostics market, by technology, 2018 - 2030 (USD Million)
  • TABLE 86 Thailand Point-of-care Molecular Diagnostics market, by test location, 2018 - 2030 (USD Million)
  • TABLE 87 Thailand Point-of-care Molecular Diagnostics market, by End-use, 2018 - 2030 (USD Million)
  • TABLE 88 Latin America Point-of-care Molecular Diagnostics market, by country, 2018 - 2030 (USD Million)
  • TABLE 89 Latin America Point-of-care Molecular Diagnostics market, by application, 2018 - 2030 (USD Million)
  • TABLE 90 Latin America Point-of-care Molecular Diagnostics market, by technology, 2018 - 2030 (USD Million)
  • TABLE 91 Latin America Point-of-care Molecular Diagnostics market, by test location, 2018 - 2030 (USD Million)
  • TABLE 92 Latin America Point-of-care Molecular Diagnostics market, by End-use, 2018 - 2030 (USD Million)
  • TABLE 93 Brazil Point-of-care Molecular Diagnostics market, by application, 2018 - 2030 (USD Million)
  • TABLE 94 Brazil Point-of-care Molecular Diagnostics market, by technology, 2018 - 2030 (USD Million)
  • TABLE 95 Brazil Point-of-care Molecular Diagnostics market, by test location, 2018 - 2030 (USD Million)
  • TABLE 96 Brazil Point-of-care Molecular Diagnostics market, by End-use, 2018 - 2030 (USD Million)
  • TABLE 97 Mexico Point-of-care Molecular Diagnostics market, by application, 2018 - 2030 (USD Million)
  • TABLE 98 Mexico Point-of-care Molecular Diagnostics market, by technology, 2018 - 2030 (USD Million)
  • TABLE 99 Mexico Point-of-care Molecular Diagnostics market, by test location, 2018 - 2030 (USD Million)
  • TABLE 100 Mexico Point-of-care Molecular Diagnostics market, by End-use, 2018 - 2030 (USD Million)
  • TABLE 101 Argentina Point-of-care Molecular Diagnostics market, by application, 2018 - 2030 (USD Million)
  • TABLE 102 Argentina Point-of-care Molecular Diagnostics market, by technology, 2018 - 2030 (USD Million)
  • TABLE 103 Argentina Point-of-care Molecular Diagnostics market, by test location, 2018 - 2030 (USD Million)
  • TABLE 104 Argentina Point-of-care Molecular Diagnostics market, by End-use, 2018 - 2030 (USD Million)
  • TABLE 105 MEA Point-of-care Molecular Diagnostics market, by country, 2018 - 2030 (USD Million)
  • TABLE 106 MEA Point-of-care Molecular Diagnostics market, by application, 2018 - 2030 (USD Million)
  • TABLE 107 MEA Point-of-care Molecular Diagnostics market, by technology, 2018 - 2030 (USD Million)
  • TABLE 108 MEA Point-of-care Molecular Diagnostics market, by test location, 2018 - 2030 (USD Million)
  • TABLE 109 MEA Point-of-care Molecular Diagnostics market, by End-use, 2018 - 2030 (USD Million)
  • TABLE 110 South Africa Point-of-care Molecular Diagnostics market, by application, 2018 - 2030 (USD Million)
  • TABLE 111 South Africa Point-of-care Molecular Diagnostics market, by technology, 2018 - 2030 (USD Million)
  • TABLE 112 South Africa Point-of-care Molecular Diagnostics market, by test location, 2018 - 2030 (USD Million)
  • TABLE 113 South Africa Point-of-care Molecular Diagnostics market, by End-use, 2018 - 2030 (USD Million)
  • TABLE 114 Saudi Arabia Point-of-care Molecular Diagnostics market, by application, 2018 - 2030 (USD Million)
  • TABLE 115 Saudi Arabia Point-of-care Molecular Diagnostics market, by technology, 2018 - 2030 (USD Million)
  • TABLE 116 Saudi Arabia Point-of-care Molecular Diagnostics market, by test location, 2018 - 2030 (USD Million)
  • TABLE 117 Saudi Arabia Point-of-care Molecular Diagnostics market, by End-use, 2018 - 2030 (USD Million)
  • TABLE 118 UAE Point-of-care Molecular Diagnostics market, by application, 2018 - 2030 (USD Million)
  • TABLE 119 UAE Point-of-care Molecular Diagnostics market, by technology, 2018 - 2030 (USD Million)
  • TABLE 120 UAE Point-of-care Molecular Diagnostics market, by test location, 2018 - 2030 (USD Million)
  • TABLE 121 UAE Point-of-care Molecular Diagnostics market, by End-use, 2018 - 2030 (USD Million)
  • TABLE 122 Kuwait Point-of-care Molecular Diagnostics market, by application, 2018 - 2030 (USD Million)
  • TABLE 123 Kuwait Point-of-care Molecular Diagnostics market, by technology, 2018 - 2030 (USD Million)
  • TABLE 124 Kuwait Point-of-care Molecular Diagnostics market, by test location, 2018 - 2030 (USD Million)
  • TABLE 125 Kuwait Point-of-care Molecular Diagnostics market, by End-use, 2018 - 2030 (USD Million)

List of Figures

  • FIG. 1 Point-of-care Molecular Diagnostics Market Segmentation
  • FIG. 2 Global Point-of-care Molecular Diagnostics Market, 2018 - 2030 (USD Million)
  • FIG. 3 Point-of-care Molecular Diagnostics Market Dynamics
  • FIG. 4 Key opportunities prioritized, 2018
  • FIG. 5 Point-of-care Molecular Diagnostics Market - Porter's Analysis
  • FIG. 6 Point-of-care Molecular Diagnostics Market - PESTEL analysis
  • FIG. 7 Point-of-care Molecular Diagnostics revenue share, by application, 2023 & 2030
  • FIG. 8 POC MDx Infectious Diseases Market, 2018 - 2030 (USD Million)
  • FIG. 9 POC MDx Oncology Market, 2018 - 2030 (USD Million)
  • FIG. 10 POC MDx Hematology Market, 2018 - 2030 (USD Million)
  • FIG. 11 POC MDx Prenatal Testing Market, 2018 - 2030 (USD Million)
  • FIG. 12 POC MDx Endocrinology Market, 2018 - 2030 (USD Million)
  • FIG. 13 POC MDx Other Applications Market, 2018 - 2030 (USD Million)
  • FIG. 14 Point-of-care Molecular Diagnostics revenue share, by technology, 2023 & 2030
  • FIG. 15 POC MDx PCR-based Market, 2018 - 2030 (USD Million)
  • FIG. 16 POC MDx Genetic Sequencing-based Market, 2018 - 2030 (USD Million)
  • FIG. 17 POC MDx Hybridization-based Market, 2018 - 2030 (USD Million)
  • FIG. 18 POC MDx Microarray-based Market, 2018 - 2030 (USD Million)
  • FIG. 19 Point-of-care Molecular Diagnostics revenue share, by test location, 2023 & 2030
  • FIG. 20 POC MDx over-the-counter Market, 2018 - 2030 (USD Million)
  • FIG. 21 POC MDx point-of-care Market, 2018 - 2030 (USD Million)
  • FIG. 22 Point-of-care Molecular Diagnostics revenue share, by End-use, 2023 & 2030
  • FIG. 23 POC MDx Decentralized Labs Market, 2018 - 2030 (USD Million)
  • FIG. 24 POC MDx Hospitals Market, 2018 - 2030 (USD Million)
  • FIG. 25 POC MDx Home-care Market, 2018 - 2030 (USD Million)
  • FIG. 26 POC MDx Assisted Living Healthcare Facilities Market, 2018 - 2030 (USD Million)
  • FIG. 27 POC MDx Other uses Market, 2018 - 2030 (USD Million)
  • FIG. 28 Point-of-care Molecular Diagnostics revenue share, by test location, 2023 & 2030
  • FIG. 29 POC MDx OTC Market, 2018 - 2030 (USD Million)
  • FIG. 30 POC MDx POC Market, 2018 - 2030 (USD Million)
  • FIG. 31 Point-of-care Molecular Diagnostics revenue share, by region, 2023 & 2030
  • FIG. 32 North America Point-of-care Molecular Diagnostics Market, 2018 - 2030 (USD Million)
  • FIG. 33 US Point-of-care Molecular Diagnostics Market, 2018 - 2030 (USD Million)
  • FIG. 34 Canada Point-of-care Molecular Diagnostics Market, 2018 - 2030 (USD Million)
  • FIG. 35 Europe Point-of-care Molecular Diagnostics Market, 2018 - 2030 (USD Million)
  • FIG. 36 Germany Point-of-care Molecular Diagnostics Market, 2018 - 2030 (USD Million)
  • FIG. 37 UK Point-of-care Molecular Diagnostics Market, 2018 - 2030 (USD Million)
  • FIG. 38 France Point-of-care Molecular Diagnostics Market, 2018 - 2030 (USD Million)
  • FIG. 39 Italy Point-of-care Molecular Diagnostics Market, 2018 - 2030 (USD Million)
  • FIG. 40 Spain Point-of-care Molecular Diagnostics Market, 2018 - 2030 (USD Million)
  • FIG. 41 Denmark Point-of-care Molecular Diagnostics Market, 2018 - 2030 (USD Million)
  • FIG. 42 Sweden Point-of-care Molecular Diagnostics Market, 2018 - 2030 (USD Million)
  • FIG. 43 Norway Point-of-care Molecular Diagnostics Market, 2018 - 2030 (USD Million)
  • FIG. 44 Asia Pacific Point-of-care Molecular Diagnostics Market, 2018 - 2030 (USD Million)
  • FIG. 45 Japan Point-of-care Molecular Diagnostics Market, 2018 - 2030 (USD Million)
  • FIG. 46 China Point-of-care Molecular Diagnostics Market, 2018 - 2030 (USD Million)
  • FIG. 47 India Point-of-care Molecular Diagnostics Market, 2018 - 2030 (USD Million)
  • FIG. 48 Australia Point-of-care Molecular Diagnostics Market, 2018 - 2030 (USD Million)
  • FIG. 49 South Korea Point-of-care Molecular Diagnostics Market, 2018 - 2030 (USD Million)
  • FIG. 50 Thailand Point-of-care Molecular Diagnostics Market, 2018 - 2030 (USD Million)
  • FIG. 51 Latin America Point-of-care Molecular Diagnostics Market, 2018 - 2030 (USD Million)
  • FIG. 52 Brazil Point-of-care Molecular Diagnostics Market, 2018 - 2030 (USD Million)
  • FIG. 53 Mexico Point-of-care Molecular Diagnostics Market, 2018 - 2030 (USD Million)
  • FIG. 54 Argentina Point-of-care Molecular Diagnostics Market, 2018 - 2030 (USD Million)
  • FIG. 55 MEA Point-of-care Molecular Diagnostics Market, 2018 - 2030 (USD Million)
  • FIG. 56 South Africa Point-of-care Molecular Diagnostics Market, 2018 - 2030 (USD Million)
  • FIG. 57 Saudi Arabia Point-of-care Molecular Diagnostics Market, 2018 - 2030 (USD Million)
  • FIG. 58 UAE Point-of-care Molecular Diagnostics Market, 2018 - 2030 (USD Million)
  • FIG. 59 Kuwait Point-of-care Molecular Diagnostics Market, 2018 - 2030 (USD Million)